Contact this trialFirst, we need to learn more about you.
Nrf2 Activator
Bardoxolone Methyl (RTA 402) for Type 2 Diabetes
Recruiting0 awardsPhase 2
Middlebury, Connecticut
This study assesses the effects of bardoxolone methyl (RTA 402) in patients with type 2 diabetes and chronic kidney disease.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service